The regulation of transcription from Epstein-Barr virus promoters is known to involve the association 30 of the host CCCTC-binding factor (CTCF) protein. This control involves direct binding of CTCF across 31 the EBV genome and the formation of three-dimensional loops between virus promoters and enhancers. 32
Introduction 57

Epstein-Barr virus (EBV) is a member of the human gammaherpesvirus family and is commonly known 58
for its association with infectious mononucleosis/glandular fever. However, EBV is also closely linked 59 with as many as 1.5% of all human cancers including B-cell lymphomas and epithelial malignancies, 60 such as Burkitt's (BL) and Hodgkin's lymphomas (HL) and nasopharyngeal carcinoma (NPC), 61 respectively (Plummer, 2016; Farrell, 2018) . The association of EBV with different diseases is 62 characterised by distinct transcription profiles of EBV nuclear antigens (EBNAs) and latent membrane 63 proteins (LMPs) in conjunction with the differentiation status of the infected B-cell. Latency type I, 64 mostly associated with BL and proliferating infected memory B-cells, involves transcription from the 65 Q-promoter (Qp) of EBNA1, a DNA binding protein that is able to tether the viral episome to cellular 66 chromosomes, thereby maintaining the EBV genome in dividing cells (Westhoff Smith, 2013) . In 67 contrast, latency type II is associated with expression of LMP1 and LMP2 as well as Qp-driven EBNA1. 68
Finally, latency type III (also known as the 'growth' program) comprises expression of the LMPs as 69 well as EBNA1, 2, 3A-C and -LP via alternatively spliced polycistronic transcripts driven initially from 70 the W-promoter (Wp), and subsequently from the C-promoter (Cp) (Rowe, 1987) , partly due to EBNA2 71 recruitment (Woisetschlaeger, 1991; Altmann, 2006) . 72
73
Programs of transcription during latency are driven from separate viral promoters on the EBV genome 74 and are known to be regulated, at least in part, through modification of chromatin on the viral genome 75 (Tempera, 2014; Hammerschmidt, 2015) . The activity of Cp is also controlled by interaction with the 76 'plasmid origin of replication' (OriP), which acts as an enhancer (Reisman, 1986; Altmann, 2006 ; 77 Puglielli, 2006) . EBNA2 association further allows the recruitment and stimulation of RNA polymerase 78 II (RNAPII) at Cp (Bark-Jones, 2006; Palermo, 2008) . Recruitment of EBNA2 to Cp is thought to be, 79 at least in part, directed by the presence of a binding site for RBPJκ, a host protein that binds to EBNA2 80 and co-localises with most EBNA2 binding sites on the genome (Ling, 1993; Zhao, 2011) . 81 82 Interestingly, a host protein known as CCCTC-binding factor (CTCF) has been shown to be important 83 in the regulation of gene expression of a number of human DNA viruses (Pentland, 2015) and is also 84 able to bind to several locations on the EBV episome, including a latency III-specific site between OriP 85 and Cp (Tempera, 2010). CTCF, a host genomic architectural protein, was first shown to bind upstream 86 of Cp by DNA affinity pulldown, electrophorectic mobility shift assay (EMSA), DNAseI footprinting 87 assay and chromatin immunoprecipitation (ChIP) assay (Chau 2004; Chau, 2006; Tempera, 2010 ; 88 Lupey-Green, 2018). This has more recently been confirmed by ChIP-seq (Holdorf, 2011; Lupey-89 Green, 2018) and has led to our understanding of its importance in the regulation of Cp activity both in 90 latency type I and type III. Initial findings suggested that CTCF was acting as a boundary element, 91 controlling transcription from Cp (Chau, 2004) . However, further investigation has shown the necessity 92 for other CTCF binding sites to be present in the EBV genome to form chromatin loops between the 93
OriP enhancer element and both Cp and Qp (Tempera, 2011). Hence, the multi-factorial manner by 94 which EBV Cp transcription is controlled throughout infection is still not fully understood. We took 95 advantage of cell lines that had previously been produced via infection with recombinant EBV in which 96
Cp had been genetically modified (Evans, 1996) to further investigate this regulation. 97
98
Isolation of in vivo EBV-infected B-cells from peripheral blood usually allows their culture in vitro as 99 lymphoblastoid cell lines (LCLs). Alternatively, this process can also be performed directly in vitro 100 through EBV infection of isolated B-cells in the laboratory. These LCLs normally express EBV proteins 101 consistent with latency type III and, with this in mind, the previous authors (Evans, 1996) sought to 102 investigate the association of both the RBPJκ binding site and also glucocorticoid response elements 103 (GREs) present between OriP and Cp. Assessment of these two sites was done independently by either 104 deletion of the GRE region (262bp at B95-8 coordinates 10221-10482) or mutation of the RBPJκ 105 binding site (GTGGGAAA to GTGAATTC at B95-8 coordinates 10959 -10966). Deletion of the GRE 106 region gave rise to up-regulation in Cp transcript level, whereas RBPJκ binding site mutation resulted 107 in a modest decrease in Cp activity (Evans, 1996) . Unintentionally, the deletion that removed the GREs 108 from Cp overlaps with the now known CTCF binding site in Cp (ranging between coordinates 10401-109 10594 by various methods) (Chau, 2006) (Figure 1 ). We were therefore able to use these cell lines to 110 investigate whether the deletion of such an intrinsic CTCF binding site upstream of Cp gave rise to 111 changes in transcript levels associated with additional EBV promoters and whether the recruitment of 112 transcription factors such as EBNA2 was altered in any way. 113
114
Results
115
We first tested the previous publication's observations (Evans, 1996) of how Cp transcript levels were 116 affected by the deletions shown in Figure 1 , before assessing whether these deletions affected 117 transcription from the alternative EBV latency-associated promoters Wp and Qp. Using qPCR we show 118 that, relative to transcription from a wild-type B95-8 EBV infection (Figure 2A The control of gene expression from the EBV genome through the regulation of transcription is known 149 to be integral to the establishment of infection of this virus but also the shifting of latency type 150 depending on the cellular environment that the virus finds itself in. Consequently, EBV has evolved to 151 regulate its own expression from a small number of viral promoters that can modulate the expression 152 level of various latency-associated genes. Through the work of a number of laboratories, we know that 153 CTCF is an important cellular factor associated with the control of EBV gene expression. Yet, it is still 154 incompletely understood how CTCF applies this control on promoters such as Cp. Hence, we undertook 155 to investigate how the deletion of a CTCF binding site upstream from Cp affected transcription from 156 various EBV promoters and also whether the association of the viral transactivator EBNA2 was in any 157 way modulated. 158
159
We found that deletion of the CTCF binding site upstream of Cp led to up-regulation of transcription 160 from Cp (Figure 2 ), as was reported in the original work with these cell lines (Evans, 1996) and for a 161
Cp-CTCF binding site deletion mutant EBV used elsewhere (Chau, 2006) . In contrast, though, the 162 modest decrease in Cp activation that the previous authors saw with RBPJκ binding site mutation was 163 not replicated here, where a subtle increase in transcription from both Cp and Wp was seen in RBPJmut. 164
This difference may be due to the reduced number of cell lines available for use here, although it is 165 important to note that our transcript data here are fully quantitative in comparison previous semi-166 quantitative PCRs (Evans, 1996) . 167 168 Despite the decrease in the level of Wp driven transcript -which can also code for EBNA2 -associated 169 with Cp-CTCF binding site deletion, the cumulative outcome was an increase in EBNA2 protein 170 expression ( Figure 3) . As previously reported (Evans, 1996) , the fold changes in transcript and protein 171 level within cells lines do not fully correlate, adding to speculation that expression level of EBV proteins 172 such as EBNA2 are very likely to be controlled at a post-transcriptional stage, at least in part due to the 173 stability of both the coding transcripts and also the protein itself. The small decrease seen in EBNA2 174 protein level with mutation of the RBPJκ binding site in Cp, however statistically significant, appears 175 unlikely to be functional as recruitment to the LMP2a promoter ( Figure 4D Therefore, it appears that CTCF may be involved in the regulation of latency type during EBV infection. 235
It has been reported that another mutant EBV genome without the Cp-CTCF binding site was able to 236 shift to latency type I, despite showing continued expression from Cp in comparison to the wild-type 237 virus, in a B-cell superinfection model (Hughes, 2012) . However, total cellular CTCF levels were not 238 analysed here. Thus, it appears that, although CTCF contributes to the establishment and restriction of 239 latency type, it may not be essential for maintenance of latency type. 
Materials & Methods 252
Cell lines 253
Established lymphoblastoid cell lines (LCLs) used in this study were first described elsewhere (Evans, 254 1996) and were a kind gift from Prof. Paul Farrell (Imperial College London). In short, wild-type EBV-255 infected LCLs (WT; BC36, BC37, SKS4.2, SKS4.3) acted as controls for Cp-CTCF binding site deleted 256 EBV-infected LCLs (ΔCTCFbs; GR2, GR104, GR112) and Cp-RBPJκ binding site mutated EBV-257 infected LCLs (RBPmut; E3, E108, E139). All cells were grown in RPMI supplemented with 10% FCS, 258 penicillin and streptomycin (Sigma) and were split 1∶3 twice a week to maintain growth in culture. 
SDS-PAGE and Western blotting 271
In short, protein extracts were resolved by sodium dodecyl sulphate-polyacrylamide gel electrophoresis 272 (SDS-PAGE) and transferred to nitrocellulose membranes before Western blot analysis was performed 273 using an ECL kit (Amersham) for visualization of protein levels, all as described previously (Anderton, 274 2007) . Protein extractions were performed at least twice and representative results are shown. Primary 275 antibodies used were: monoclonal antibodies against EBNA2 (clone PE2; DAKO), RBPJk (ab25949; 276
Abcam) and γ-Tubulin (T6557; Sigma). Semi-quantitative analysis of protein levels was carried out 277 using Image J software and comparative densitometry to γ-Tubulin loading levels. 278
Chromatin Immunoprecipitation 280
Chromatin immunoprecipitation (ChIP) assays were carried out using a ChIP Assay Kit (17-295; 281 Millipore) according to the manufacturer's instructions, as described previously (Paschos, 2009) . Table 1 . 292
293
Conflict of interest statement 294
The corresponding author declares that there are no competing interests. Values are means (+1SD) of at least three biological replicates and two technical replicates, and relative to wild-type controls. P-value determined by Student's T-test (*P<0.05; **P<0.01). Δ = deletion of this site in ∆CTCFbs LCLs.
